Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD BeovuⓇ - Anti-VEGF Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04047472 HOBBY (CRTH258A2307) Macular degeneration Phase 3 494 Change from baseline in best-corrected visual acuity (BCVA) at week 48 Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Chinese patients with neovascular age-related macular degeneration Target Patients Read-out Milesstone(s) 2024 Publication TBD 96 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation